Maryam Sadri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maryam Sadri has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ali-Akbar Delbandi
Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
2 shared publications - Mahzad Akbarpour
Universal Scientific Education and Research Network (USERN)
2 shared publications - Pooya Farhangnia
Iran University of Medical Sciences
2 shared publications - Ahmad Vosoughi Motlagh
Department of Pediatrics, North Khorasan University of Medical Sciences, Bojnurd, Iran
1 shared publication - Fatemeh Faraji
Immunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran
1 shared publication - Fatemeh Kheiri
Iran University of Medical Sciences
1 shared publication
Latest Publications
- 13 August 2026
- Published by Taylor & Francis in Immunotherapy
- Vol. 18 (11-12) , 1029-1054
Cancer vaccines as targeted therapies: translational advances and challenges
- 13 August 2026
- Published by Taylor & Francis in Immunotherapy
- Vol. 18 (11-12) , 1029-1054
Cancer vaccines as targeted therapies: translational advances and challenges
- Open Access
- 27 April 2026
- Published by Maad Rayan Publishing Company in Biomedicine Advances
- Vol. 3 (2) , 72-82
Aging may alter immune responses to COVID-19 vaccination
The immune system weakens with age through immunosenescence, making older adults more vulnerable to infections and cancers. Viral pandemics like COVID-19 hit this group hardest, with the elderly facing the highest infection and death rates, especially those with underlying conditions. With the global older population expected to double by 2050, future outbreaks will continue to target this age group. Recent vaccine research shows that aging alters immune responses in complex ways. While older individuals may produce similar levels of neutralizing antibodies after repeated vaccination, other protective functions, like antibody-dependent cellular cytotoxicity, decline significantly. The broad immunity that defends against multiple virus strains also appears impaired in the elderly. Given these findings and the limitations of herd immunity strategies, strengthening elderly immune systems through proper nutrition, healthy lifestyles, and tailored vaccination approaches is critical. Standard vaccines may not be enough. Designing vaccines and schedules specifically to overcome aging-related immune weaknesses should be a priority for protecting this growing population against future pandemics.
- 27 April 2026
- Published by Maad Rayan Publishing Company in Biomedicine Advances
- Vol. 3 (2) , 72-82
Open AccessAging may alter immune responses to COVID-19 vaccination
The immune system weakens with age through immunosenescence, making older adults more vulnerable to infections and cancers. Viral pandemics like COVID-19 hit this group hardest, with the elderly facing the highest infection and death rates, especially those with underlying conditions. With the global older population expected to double by 2050, future outbreaks will continue to target this age group. Recent vaccine research shows that aging alters immune responses in complex ways. While older individuals may produce similar levels of neutralizing antibodies after repeated vaccination, other protective functions, like antibody-dependent cellular cytotoxicity, decline significantly. The broad immunity that defends against multiple virus strains also appears impaired in the elderly. Given these findings and the limitations of herd immunity strategies, strengthening elderly immune systems through proper nutrition, healthy lifestyles, and tailored vaccination approaches is critical. Standard vaccines may not be enough. Designing vaccines and schedules specifically to overcome aging-related immune weaknesses should be a priority for protecting this growing population against future pandemics.
- 1 October 2025
- Published by Springer Nature
- p. 207-251
Bispecific Antibodies in Targeted Cancer Immunotherapy
- 1 October 2025
- Published by Springer Nature
- p. 207-251
Bispecific Antibodies in Targeted Cancer Immunotherapy
- 26 January 2023
- Published by Springer Nature
- p. 1-46
Bispecific Antibodies in Targeted Cancer Immunotherapy
- 26 January 2023
- Published by Springer Nature
- p. 1-46
Bispecific Antibodies in Targeted Cancer Immunotherapy